GALIG Gene Expression in Parkinson's Disease

Not Applicable

Completed

• Conditions: Parkinson Disease
• Interventions: Other: Blood sampling

• Registration Number: NCT02923297
• Lead Sponsor: Centre Hospitalier Régional d'Orléans

Brief Summary

Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04
• Primary Completion: 2015-06-30
• Study Completion: 2015-06-30
• Study First Submitted: 2016-10-03
• Study First Submitted QC: 2016-10-03
• Study First Posted: 2016-10-04
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-31
• Last Update Posted: 2020-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Read More

Exclusion Criteria

• Insane patient arriving without a third party.
• Patient with Parkinson's disease arising from another etiology.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Parkinson's disease patients	Blood sampling	blood sampling

Primary Outcome Measures

Name	Time	Method
RNA (ribonucleic acid) assay of SNCA genes	Day 0	Only one assessment in the study
RNA (ribonucleic acid) assay of GALIG gene	Day 0	Only one assessment in the study

Trial Locations

Locations (1)

CHR d'ORLEANS; 🇫🇷 Orleans, France